8-K current report · filed Nov 5, 2026

FATE THERAPEUTICS INC (FATE) 8-K Current Report: November 5, 2026

Item 1.01Item 1.02FATE overview

Short answer

FATE THERAPEUTICS INC (FATE) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement). ATM equity program authorizes up to $100 million in common-stock sales, providing Fate with flexible funding access.

FATE THERAPEUTICS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • ATM equity program authorizes up to $100 million in common-stock sales, providing Fate with flexible funding access
  • Share issuance remains discretionary, limiting immediate dilution but creating potential dilution if capital is raised
  • Leerink Partners commission up to 3.0% of gross proceeds, reducing net cash raised
  • Existing S-3 expires November 27, 2026, with planned replacement registration enabling continued sales through May 26, 2027

Item 1.02 · Termination of a Material Definitive Agreement

  • Jefferies ATM agreement terminated November 5, 2026, replaced in connection with a new Sales Agreement
  • 2,801,602 shares sold for $8.0 million gross proceeds under the terminated facility
  • No termination penalties, eliminating obligations under the Jefferies arrangement
  • Former facility allowed up to $100.0 million in common-stock sales, but remaining capacity is no longer usable

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other FATE THERAPEUTICS INC 8-K filings

Get the next FATE 8-K as it lands

Follow FATE for push alerts, or ask the research agent what this filing means.